Unknown

Dataset Information

0

A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS.


ABSTRACT: BACKGROUND:Acute respiratory distress syndrome (ARDS) is a prevalent disease with significant mortality for which no effective pharmacologic therapy exists. Low-dose inhaled carbon monoxide (iCO) confers cytoprotection in preclinical models of sepsis and ARDS. METHODS:We conducted a phase I dose escalation trial to assess feasibility and safety of low-dose iCO administration in patients with sepsis-induced ARDS. Twelve participants were randomized to iCO or placebo air 2:1 in two cohorts. Four subjects each were administered iCO (100 ppm in cohort 1 or 200 ppm in cohort 2) or placebo for 90 minutes for up to 5 consecutive days. Primary outcomes included the incidence of carboxyhemoglobin (COHb) level ?10%, prespecified administration-associated adverse events (AEs), and severe adverse events (SAEs). Secondary endpoints included the accuracy of the Coburn-Forster-Kane (CFK) equation to predict COHb levels, biomarker levels, and clinical outcomes. RESULTS:No participants exceeded a COHb level of 10%, and there were no administration-associated AEs or study-related SAEs. CO-treated participants had a significant increase in COHb (3.48% ± 0.7% [cohort 1]; 4.9% ± 0.28% [cohort 2]) compared with placebo-treated subjects (1.97% ± 0.39%). The CFK equation was highly accurate at predicting COHb levels, particularly in cohort 2 (R2 = 0.9205; P < 0.0001). Circulating mitochondrial DNA levels were reduced in iCO-treated participants compared with placebo-treated subjects. CONCLUSION:Precise administration of low-dose iCO is feasible, well-tolerated, and appears to be safe in patients with sepsis-induced ARDS. Excellent agreement between predicted and observed COHb should ensure that COHb levels remain in the target range during future efficacy trials. TRIAL REGISTRATION:ClinicalTrials.gov NCT02425579. FUNDING:NIH grants P01HL108801, KL2TR002385, K08HL130557, and K08GM102695.

SUBMITTER: Fredenburgh LE 

PROVIDER: S-EPMC6328240 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS.

Fredenburgh Laura E LE   Perrella Mark A MA   Barragan-Bradford Diana D   Hess Dean R DR   Peters Elizabeth E   Welty-Wolf Karen E KE   Kraft Bryan D BD   Harris R Scott RS   Maurer Rie R   Nakahira Kiichi K   Oromendia Clara C   Davies John D JD   Higuera Angelica A   Schiffer Kristen T KT   Englert Joshua A JA   Dieffenbach Paul B PB   Berlin David A DA   Lagambina Susan S   Bouthot Mark M   Sullivan Andrew I AI   Nuccio Paul F PF   Kone Mamary T MT   Malik Mona J MJ   Porras Maria Angelica Pabon MAP   Finkelsztein Eli E   Winkler Tilo T   Hurwitz Shelley S   Serhan Charles N CN   Piantadosi Claude A CA   Baron Rebecca M RM   Thompson B Taylor BT   Choi Augustine Mk AM  

JCI insight 20181206 23


<h4>Background</h4>Acute respiratory distress syndrome (ARDS) is a prevalent disease with significant mortality for which no effective pharmacologic therapy exists. Low-dose inhaled carbon monoxide (iCO) confers cytoprotection in preclinical models of sepsis and ARDS.<h4>Methods</h4>We conducted a phase I dose escalation trial to assess feasibility and safety of low-dose iCO administration in patients with sepsis-induced ARDS. Twelve participants were randomized to iCO or placebo air 2:1 in two  ...[more]

Similar Datasets

| S-EPMC6026220 | biostudies-literature
2022-10-21 | GSE173986 | GEO
| S-EPMC7714055 | biostudies-literature
| S-EPMC4683310 | biostudies-literature
2008-05-29 | GSE11095 | GEO
2008-05-29 | E-GEOD-11095 | biostudies-arrayexpress
| S-EPMC5770048 | biostudies-literature
| S-EPMC2770753 | biostudies-literature
| S-EPMC1773787 | biostudies-literature
| S-EPMC4786624 | biostudies-literature